|
Reference
|
Year
|
Inclusion period
|
Sample size (total/BEV)
|
Study type
|
CTX in BEV group OX/IRI/OX + IRI [%]
|
No BEV cycles
|
Interval last BEV cycle to surgery
|
Risk of bias
|
|---|
|
Aussilhou
|
2009
|
2002–2008
|
40/13
|
Prosp. CS
|
54/38
|
12 (2–36)
|
92 days
|
High
|
|
Constantinidou
|
2013
|
Until 9/2010
|
94/42
|
Retrosp. CS
|
64/33
|
4.5 (4–12)a
|
73 (44–141) days
|
High
|
|
D’Angelica
|
2007
|
2004–2005
|
64/32
|
Matched CCS
|
56/37
|
9 (4–15)
|
6.9 (3–15) weeks
|
High
|
|
Kesmodel
|
2008
|
2004–2006
|
125/81
|
Retrosp. CS
|
70/36
|
84 (14–513)b
|
58 (31–117) days
|
High
|
|
Klinger
|
2009
|
2001–2006
|
106/56
|
Retrosp. CSe
|
100/0
|
5
|
5 weeks
|
High
|
|
Lubezky
|
2013
|
2000–2007
|
191/134
|
Retrosp. CS
|
72/28
|
-
|
>6 weeks
|
High
|
|
Mahfud
|
2010
|
2005–2007
|
90/45
|
Matched CCS
|
24/71
|
9 (7–10)a
|
9 weeks (60, 47–73 days)
|
Low
|
|
Millet
|
2012
|
2006–2011
|
82/41
|
Matched CCS
|
15/85
|
6 (4–16)a
|
65 (39–90) days
|
Low
|
|
Pessaux
|
2010
|
2005–2007
|
42/21
|
Matched CCS
|
76/10/14
|
8.1 ± 4.7
|
11.7 ± 4.7 weeks
|
Low
|
|
Reddy
|
2008
|
1996–2006
|
96/39
|
Retrosp. CS
|
79/21
|
6 (3–8)c
|
10 (8–13) weeks
|
High
|
|
Ribero
|
2007
|
2002–2006
|
105/62
|
Retrosp. CS
|
100/0
|
6 (3–12)a
|
>6 weeks
|
High
|
|
Rong
|
2014
|
2002–2012
|
501/117
|
Retrosp. CS
|
100/0
|
6 ± 12a
|
-
|
High
|
|
Rubbia Brandt
|
2010
|
–
|
274/70d
|
Retrosp. CS
|
100/0
|
-
|
-
|
High
|
|
Tamandl
|
2009
|
2005–2009
|
214/102
|
Retrosp. CS
|
82/13
|
6 (1–20)
|
34 (17–99) days
|
High
|
|
van der Pool
|
2012
|
2003–2008
|
104/51
|
Retrosp. CS
|
100/0
|
4 (1–15)a
|
11 (5–38) weeks
|
High
|
|
Vera
|
2014
|
2005–2011
|
95/51
|
Retrosp. CS
|
45/53
|
6 (1–21)a
|
-
|
High
|
|
Wicherts
|
2011
|
2005–2009
|
164/67
|
Retrosp. CS
|
23/68/2
|
8.6 (1–34)
|
8 (3–19) weeks
|
Low
|
|
Zorzi
|
2008
|
1995–2007
|
43/26
|
Retrosp. CS
|
100/0
|
5 (3–20)a
|
7.9 (3–36) weeks
|
High
|
- aNumber of CTx cycles
- bDuration of BEV treatment in days
- cDuration of BEV treatment in months
- dIrinotecan was added in 79 patients of the whole study cohort
- eCombined retrospective analysis of two phase II trials. Continuous data are presented as median (range) or mean (standard deviation) based on the kind of data presented in the original publication
